title: Respiratory syncytial virus season and hospitalizations in the Alaskan Yukon-Kuskokwim Delta.
abstract: From 1993 to 1996, Alaska Native infants younger than 1 year of age from the Yukon-Kuskokwim Delta region in Alaska experienced a respiratory syncytial virus (RSV) hospitalization rate 5 times higher than the U.S. general infant population rate. This article describes the trends in hospitalization and prolonged annual season of RSV hospitalizations in Yukon-Kuskokwim children from 1993 to 2004 and discusses factors associated with high rates of RSV hospitalization and the impact of interventions to decrease RSV hospitalizations in this population.
authors: Alaska Native Tribal Health Consortium, Anchorage, AK 99508, USA. ris2@cdc.gov
authors: Rosalyn J
authors: RJ
authors: Singleton
authors: Dana
authors: D
authors: Bruden
authors: Lisa R
authors: LR
authors: Bulkow
mesh_terms: D000413:Alaska / Q000453:epidemiology / Q000208:ethnology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D002675:Child, Preschool; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000208:ethnology* / Q000821:virology; D018113:Respiratory Syncytial Virus, Human / Q000302:isolation & purification*; D012621:Seasons
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab